Loading…
Capricor Therapeutics, Inc. is projected to rise to $38.40 by 2027, a +32% move from its current price of $29.14. CAPR is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 5/28/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| May 29 | $28.13 | $29.14 | $30.19 | +0.01% |
| May 30 | $27.73 | $29.14 | $30.64 | +0.01% |
| May 31 | $27.42 | $29.15 | $30.98 | +0.02% |
| Jun 1 | $27.16 | $29.15 | $31.28 | +0.03% |
| Jun 2 | $26.94 | $29.15 | $31.54 | +0.04% |
| Jun 3 | $26.74 | $29.15 | $31.78 | +0.04% |
| Jun 4 | $26.56 | $29.16 | $32.01 | +0.05% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $26.56 | $29.16 | $32.01 | +0.05% |
| Week 2 | $25.56 | $29.17 | $33.29 | +0.10% |
| Week 3 | $24.83 | $29.19 | $34.31 | +0.15% |
| Week 4 | $24.23 | $29.20 | $35.19 | +0.21% |
| Week 5 | $23.71 | $29.22 | $36.00 | +0.26% |
| Week 6 | $23.25 | $29.23 | $36.74 | +0.31% |
| Week 7 | $22.84 | $29.25 | $37.44 | +0.36% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Capricor Therapeutics, Inc. is a clinical-stage biotechnology company in the Healthcare sector that develops transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD.
The company was founded in 2005 and is headquartered in San Diego, California. It also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and exosome platform program consists of engineered exosomes for vaccine and therapeutic development and is in preclinical trial. Capricor has license agreements with Johns Hopkins University, University of Rome License, and Cedars-Sinai Medical Center to develop and commercialize licensed products and licensed services under the licensed patent rights in all fields and a nonexclusive right to the know-how; Cell Line License Agreement with Life Technologies for the development of exosomes platform.
Capricor Therapeutics, Inc. (CAPR) is currently priced at $28.87 per share and has a market capitalization of $1.67B, ranking 2142. The current price is paired with a forecast that places the 2026 average at $28.87 within a 2026 range of $21.57 to $43.35, with a Neutral sentiment for that year.
Looking further ahead, the forecast shows a rising path: 2030 average $46.40 (ROI 60.7), 2040 average $136.06 (ROI 371.3), and 2050 average $298.36 (ROI 933.5). Max forecast values climb to $72.79 (2030), $256.80 (2040), and $627.76 (2050), illustrating substantial upside potential if realized.
A major floor 26.0% below — a decisive break under it would weaken the trend.
The nearest floor, 7.6% below — buyers have tended to step in here.
The nearest ceiling, 21.3% above — a clean break opens room to run.
A major ceiling 33.4% above — clearing it would confirm fresh momentum.
Key CAPR support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of CAPR market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $29.19 | Sell | $29.12 | Buy |
| MA 10 | $28.98 | Buy | $29.47 | Sell |
| MA 20 | $30.77 | Sell | $30.37 | Sell |
| MA 50 | $31.61 | Sell | $30.55 | Sell |
| MA 100 | $28.77 | Buy | $27.96 | Buy |
| MA 200 | $19.78 | Buy | $23.04 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 44.03 | Neutral |
| Stoch RSI (14) | 49.47 | Neutral |
| CCI (20) | -59.51 | Neutral |
| Williams %R (14) | -68.38 | Info |
| MACD (12,26,9) | -0.20 | Sell |
| ROC (12) | -4.08 | Sell |
| Bollinger %B (20,2) | 0.31 | Neutral |
| Stochastic %K (14) | 31.62 | Neutral |
| TRIX (15) | -0.37 | Sell |
| Awesome (5,34) | -3.00 | Sell |
| Ultimate (7,14,28) | 45.26 | Neutral |
| Momentum (10) | -2.38 | Sell |
| Aroon Osc (25) | -80.00 | Sell |
| Hull MA (9) | 29.43 | Sell |
| ADX (14) | 14.99 | Neutral |
| ATR (14) | 1.01 | Info |
The 30-day technical picture is bullish, with a sentiment labeled as BULLISH. The RSI14 reads 40, indicating room for momentum development within a neutral to modestly positive range.
Key moving averages point higher: SMA50 at $31.66 and SMA200 at $19.58. Near-term support is at $26.92 and resistance at $35.34. The 30-day range spans from $22.57 to $36.93, outlining recent volatility within those bounds.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $21.57 | $29.14 | $42.95 | 0% | Neutral | |
| $29.59 | $38.40 | $53.27 | +32% | Bullish | |
| $31.16 | $41.93 | $60.79 | +44% | Bullish | |
| $30.64 | $42.51 | $63.82 | +46% | Bullish | |
| $34.33 | $48.95 | $75.66 | +68% | Bullish | |
| $41.82 | $61.15 | $96.94 | +110% | Bullish | |
| $49.85 | $74.64 | $121.06 | +156% | Bullish | |
| $55.53 | $85.01 | $140.75 | +192% | Bullish | |
| $54.14 | $84.68 | $142.88 | +191% | Bullish | |
| $56.72 | $90.57 | $155.51 | +211% | Bullish | |
| $83.74 | $147.07 | $271.65 | +405% | Bullish | |
| $154.96 | $322.97 | $662.69 | +10.1x | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| May 2026 | $21.57 | $29.14 | $34.56 | +0.00% |
| June 2026 | $25.37 | $29.99 | $36.43 | +2.92% |
| July 2026 | $24.55 | $29.34 | $36.25 | -2.18% |
| August 2026 | $24.73 | $29.80 | $37.31 | +1.58% |
| September 2026 | $25.57 | $31.04 | $39.28 | +4.15% |
| October 2026 | $25.40 | $31.04 | $39.66 | -0.00% |
| November 2026 | $25.32 | $31.11 | $40.09 | +0.25% |
| December 2026 | $26.76 | $33.06 | $42.95 | +6.28% |
Click any year to see its month-by-month CAPR forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
The CAPR price prediction for 2026 points to an average of $29.14 (low $21.57, high $42.95) — a potential gain of 0% on today's $29.14. A consolidation phase looks the most probable path here.
In 2027, CAPR is projected to trade between $29.59 and $53.27, averaging $38.40 — a potential gain of +32% from today's $29.14. That is up +32% on the projected 2026 average. Momentum favours further upside here.
Capricor Therapeutics, Inc.'s 2028 outlook centres on $41.93, within a $31.16 to $60.79 range. That is up +9% on the projected 2027 average. That marks a +44% change versus current levels. Buyers look set to stay in control over this stretch.
By 2029, CAPR could reach as high as $63.82, with a base case around $42.51 and support toward $30.64 — roughly +46% from $29.14. Momentum favours further upside here.
Expect CAPR to range from $34.33 to $75.66 through 2030. The $48.95 average target implies a +68% move from current prices. That is up +15% on the projected 2029 average. Buyers look set to stay in control over this stretch.
The CAPR price prediction for 2031 points to an average of $61.15 (low $41.82, high $96.94) — a potential gain of +110% on today's $29.14. Momentum favours further upside here.
In 2032, CAPR is projected to trade between $49.85 and $121.06, averaging $74.64 — a potential gain of +156% from today's $29.14. That is up +22% on the projected 2031 average. Buyers look set to stay in control over this stretch.
Capricor Therapeutics, Inc.'s 2033 outlook centres on $85.01, within a $55.53 to $140.75 range. That is up +14% on the projected 2032 average. That marks a +192% change versus current levels. Momentum favours further upside here.
By 2034, CAPR could reach as high as $142.88, with a base case around $84.68 and support toward $54.14 — roughly +191% from $29.14. Buyers look set to stay in control over this stretch.
Expect CAPR to range from $56.72 to $155.51 through 2035. The $90.57 average target implies a +211% move from current prices. That is up +7% on the projected 2034 average. Momentum favours further upside here.
The CAPR price prediction for 2040 points to an average of $147.07 (low $83.74, high $271.65) — a potential gain of +405% on today's $29.14. Buyers look set to stay in control over this stretch.
In 2050, CAPR is projected to trade between $154.96 and $662.69, averaging $322.97 — a potential gain of +10.1x from today's $29.14. That is up +120% on the projected 2040 average. Momentum favours further upside here.
Investing $1,000 in CAPR today (≈ 34.31709 CAPR) could be worth
$11,083.34
+$10,083.34 (+1008%) by 2050 · US Dollar
Based on the average projected CAPR price of $322.97 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in CAPRwould be worth at today's price.
$1,000 invested in CAPR on May 27, 2025 (≈ 95.419851 CAPR) would be worth
$2,780.53
+$1,780.53 (+178.1%) today · 2.78× · US Dollar
Based on a CAPR entry price of $10.48 vs. today's $29.14.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $29.01 | $1,004.48 | +0.4% |
| 1 month ago | $35.1 | $830.2 | -17.0% |
| 3 months ago | $27.89 | $1,044.82 | +4.5% |
| 6 months ago | $5.35 | $5,446.73 | +444.7% |
| 1 year ago | $10.48 | $2,780.53 | +178.1% |
| All time (5.0y) ago | $3.87 | $7,529.72 | +653.0% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our CAPR forecast.
Our base-case forecast reaches $58.00 around 2031.
Implied market cap at $58.00: $3.36B
The multi-year forecast shows a bullish trajectory, with 2027 average $37.60 and 2028 average $40.74, followed by 2029 average $41.14 and 2030 average $46.40, yielding a positive long-run outlook (ROI 60.7).
From 2031 onward, the averages continue to rise: 2031 $58.32, 2032 $71.42, 2033 $80.28, 2034 $80.13, and 2035 $85.37, all reflecting bullish sentiment in the latter part of the decade.
In the far horizon, 2040 average is $136.06 (ROI 371.3) and 2050 average is $298.36 (ROI 933.5). The forecast includes higher max values such as $93.94 in 2031, $117.79 in 2032, $135.27 in 2033, $137.69 in 2034, $149.39 in 2035, and ultimately $256.80 (2040) and $627.76 (2050).
These figures are estimates, not guarantees, and carry uncertainty and risk. Investors should consider the range of outcomes shown in the forecast when weighing CAPR's long-term potential.
Tap a question to reveal the answer.
Avg $46.40; min $32.08; max $72.79; ROI 60.7; sentiment BULLISH.
The forecast shows bullish sentiment from 2027 onward with averages rising to $37.60 (2027), $40.74 (2028), $41.14 (2029), and $46.40 (2030) with ROI 60.7; 2040 and 2050 show substantial upside (136.06 and 298.36 avg with 371.3 and 933.5 ROI). The 2026 value is Neutral.
Yes—the max forecast for 2032 is $117.79, with 2033 $135.27, 2034 $137.69, and 2035 $149.39, all above $100.
Current price is $28.87 and market cap is $1.67B.
Bullish sentiment with RSI14 at 40; SMA50 at $31.66 and SMA200 at $19.58. Support is $26.92, resistance is $35.34, and the 30-day range is $22.57–$36.93.
Capricor Therapeutics, Inc. Community Discussion
0Share your Capricor Therapeutics, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.